NEI to test Lucentis and Avastin for treating eye disorder

10/2/2006 | Bloomberg

The National Eye Institute may test Genentech's eye drug Lucentis and its cancer drug Avastin to compare the two in treating age-related macular degeneration. However, the institute said some major funding issues remain in creating the trial.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI